Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: The risk of consequent nephropathy following initial weight loss in diabetic patients treated with sodium glucose cotransporter 2 inhibitors

Fig. 1

Enrollment of patients with T2DM treated with SGLT2i. A total of 8,992 patients with T2DM treated with SGLT2i from June 1, 2016, to December 31, 2018, were recruited (A). We stratified the patients based on their baseline BMI into the following groups: underweight (BMI < 18.5 kg/m2), normal (BMI: 18.5–22.9 kg/m2), overweight (BMI: 23.0–24.9 kg/m2), pre-obese (BMI: 25.0–29.9 kg/m2), obese I (BMI: 30.0–34.9 kg/m2), and obese II (BMI: ≥ 35.0 kg/m2) subgroups. There were 38.9%, 23.5%, 24.7%, 8.4%, 2.7%, and 1.8% of patients experiencing no BW loss, an initial BW loss of 0.0–2.4%, 2.5–4.9%, 5.0–7.4%, 7.5–9.9%, and ≥ 10.0% following around 3 months of SGLT2i treatment (B). ACR albumin to creatinine ratio, BMI body mass index, BW body weight, eGFR estimated glomerular filtration rate, SGLT2i sodium–glucose cotransporter 2 inhibitor, T2DM type 2 diabetes mellitus

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840